MedicQuant has been awarded DKK 4.7 million through the Innobooster programme from Innovationsfonden.

The grant will support the continued development and analytical validation of MedicQuant’s rapid point-of-care diagnostic test for acute stroke care. The test is being developed to measure clinically relevant apixaban levels in emergency settings, where timely diagnostic information can be important for treatment decisions.

With this support, we will continue advancing our technology, analytical validation activities, and preparations for clinical validation.

Innobooster is a programme under Innovationsfonden supporting knowledge-based innovation projects in Danish companies with commercial potential.